Psoriasis

Publication of the phase 3 ARRECTOR trial findings precede an anticipated PDUFA date of May 22, 2025, for the investigational foam, now under FDA review.

The April issue covers atopic dermatitis, highlighting primary care’s role in early diagnosis, key updates from recent conferences, and more.

The findings highlight the potential of the interleukin-23 inhibitor to address a notoriously difficult-to-treat manifestation of psoriasis.

Findings showed that improved skin clearance and reduced anxiety and depression significantly influenced perceived patient benefit.